Pharmaceutical giant Moderna has signed a memorandum of understanding (MOU) with Kenya’s government for its first mRNA vaccine manufacturing facility in Africa. In a statement on Monday, the company said its goal is to produce up to 500 million doses of vaccines a year for the continent – with a focus on drug substance manufacturing, though the facility could be expanded to include fill-and-finish work. In October, Senegal and Rwanda signed an agreement with BioNTech for the construction of its first start-to-finish factories to make mRNA vaccines in Africa. The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines. Scientists hope the technology, which is easier to scale up than traditional vaccine methods, might ultimately be used to make vaccines against other diseases, including malaria.
SOURCE: AL JAZEERA
More Stories
African and Global Firms Contribute towards Harris’ Empowerment Fund
The Main Winners in Nigeria’s Botched Currency Overhaul are Two Chinese-owned Fintech Apps
The Growing Opportunities that African Pharmaceuticals Present
Africa’s Extraction and Export of Raw Materials is Rising
Accra’s Plan on a Debt-free Life
Mauto is Preparing Benin—and Africa—for an e-bike Ride
Rwanda’s Long History of Mining
Disease Stops Trade in East Africa’s Border Towns
A Marketplace for Medical Equipment in Addis
South African Rate Hike Exceeds All Expectations
At the Coalface of the Green Revolution, but Earning Crumbs
Harris Stresses that U.S. Interests in African Nations Extends beyond Competing with China